Seres Therapeutics Inc - Asset Resilience Ratio
Seres Therapeutics Inc (MCRB) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Seres Therapeutics Inc (MCRB) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2023)
This chart shows how Seres Therapeutics Inc's Asset Resilience Ratio has changed over time. See net assets of Seres Therapeutics Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Seres Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Seres Therapeutics Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Seres Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Seres Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Seres Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Seres Therapeutics Inc (2015–2023)
The table below shows the annual Asset Resilience Ratio data for Seres Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $358.60 Million | -- |
| 2022-12-31 | 5.25% | $18.31 Million | $348.78 Million | -25.95pp |
| 2021-12-31 | 31.20% | $110.70 Million | $354.86 Million | -8.92pp |
| 2020-12-31 | 40.11% | $137.57 Million | $342.94 Million | +17.70pp |
| 2019-12-31 | 22.42% | $29.69 Million | $132.44 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $120.47 Million | -- |
| 2017-12-31 | 60.10% | $113.89 Million | $189.52 Million | +9.22pp |
| 2016-12-31 | 50.87% | $138.70 Million | $272.65 Million | -9.59pp |
| 2015-12-31 | 60.47% | $131.15 Million | $216.90 Million | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outc… Read more